Updated: Updated version of guidance for laboratories, healthcare providers and healthcare professionals replaces that first published in 2016.
Candida auris is a pathogenic yeast species that has been reported to cause bloodstream infections, wound infections, and otitis. It has also been cultured from urine and the respiratory tract. Unlike other pathogenic yeast species, C. auris appears to have a propensity for transmission between hospital patients. It is commonly resistant to the first-line antifungal, fluconazole and can develop resistance to other classes of anti-fungal agents.
This document provides guidance about sending Candida spp isolates for laboratory testing, treatment and decolonisation of patients and screening in hospitals, and infection prevention and control measures.
Local copy of Updated_Candida_auris_Guidance.pdf seen at 18:33, 11 August in Publications on GOV.UK.
Email this to a friend.